Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes
Publication: Antioxidants & Redox Signaling
Volume 30, Issue Number 2
Abstract
Significance: Nicotinamide adenine dinucleotide (NAD+) is an essential pyridine nucleotide that serves as an essential cofactor and substrate for a number of critical cellular processes involved in oxidative phosphorylation and ATP production, DNA repair, epigenetically modulated gene expression, intracellular calcium signaling, and immunological functions. NAD+ depletion may occur in response to either excessive DNA damage due to free radical or ultraviolet attack, resulting in significant poly(ADP-ribose) polymerase (PARP) activation and a high turnover and subsequent depletion of NAD+, and/or chronic immune activation and inflammatory cytokine production resulting in accelerated CD38 activity and decline in NAD+ levels. Recent studies have shown that enhancing NAD+ levels can profoundly reduce oxidative cell damage in catabolic tissue, including the brain. Therefore, promotion of intracellular NAD+ anabolism represents a promising therapeutic strategy for age-associated degenerative diseases in general, and is essential to the effective realization of multiple benefits of healthy sirtuin activity. The kynurenine pathway represents the de novo NAD+ synthesis pathway in mammalian cells. NAD+ can also be produced by the NAD+ salvage pathway.
Recent Advances: In this review, we describe and discuss recent insights regarding the efficacy and benefits of the NAD+ precursors, nicotinamide (NAM), nicotinic acid (NA), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN), in attenuating NAD+ decline in degenerative disease states and physiological aging.
Critical Issues: Results obtained in recent years have shown that NAD+ precursors can play important protective roles in several diseases. However, in some cases, these precursors may vary in their ability to enhance NAD+ synthesis via their location in the NAD+ anabolic pathway. Increased synthesis of NAD+ promotes protective cell responses, further demonstrating that NAD+ is a regulatory molecule associated with several biochemical pathways.
Future Directions: In the next few years, the refinement of personalized therapy for the use of NAD+ precursors and improved detection methodologies allowing the administration of specific NAD+ precursors in the context of patients' NAD+ levels will lead to a better understanding of the therapeutic role of NAD+ precursors in human diseases.
Get full access to this article
View all available purchase options and get full access to this article.
References
1. Public Health Reports, June 26, 1914. The etiology of pellagra. The significance of certain epidemiological observations with respect thereto. Public Health Rep 90: 373–375, 1975.
2. Abeti R and Duchen MR. Activation of PARP by oxidative stress induced by beta-amyloid: implications for Alzheimer's disease. Neurochem Res 37: 2589–2596, 2012.
3. Agote M, Viaggi M, Kreimann E, Krawiec L, Dagrosa, Juvenal GJ, Pisarev. Influence of nicotinamide on the radiosensitivity of normal and goitrous thyroid in the rat. Thyroid 11: 1003–1007, 2001.
4. Agote Robertson M, Finochietto P, Gamba CA, Dagrosa MA, Viaggi ME, Franco MC, Poderoso JJ, Juvenal GJ, and Pisarev MA. Nicotinamide increases thyroid radiosensitivity by stimulating nitric oxide synthase expression and the generation of organic peroxides. Horm Metab Res 38: 12–15, 2006.
5. Aikawa H and Suzuki K. Lesions in the skin, intestine, and central nervous system induced by an antimetabolite of niacin. Am J Pathol 122: 335–342, 1986.
6. Aksoy S, Brandriff BF, Ward A, Little PF, and Weinshilboum RM. Human nicotinamide N-methyltransferase gene: molecular cloning, structural characterization and chromosomal localization. Genomics 29: 555–561, 1995.
7. Alano CC, Garnier P, Ying W, Higashi Y, Kauppinen TM, and Swanson RA. NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci 30: 2967–2978, 2010.
8. Alano CC, Ying W, and Swanson RA. Poly(ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD+ depletion and mitochondrial permeability transition. J Biol Chem 279: 18895–18902, 2004.
9. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X, Tian B, Wagner T, Vatner SF, and Sadoshima J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 100: 1512–1521, 2007.
10. Alenzi FQ. Effect of nicotinamide on experimental induced diabetes. Iran J Allergy Asthma Immunol 8: 11–18, 2009.
11. Ali YO, McCormack R, Darr A, and Zhai RG. Nicotinamide mononucleotide adenylyltransferase is a stress response protein regulated by the heat shock factor/hypoxia-inducible factor 1alpha pathway. J Biol Chem 286: 19089–19099, 2011.
12. Ali YO, Ruan K, and Zhai RG. NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy. Hum Mol Genet 21: 237–250, 2012.
13. Alrob OA, Sankaralingam S, Ma C, Wagg CS, Fillmore N, Jaswal JS, Sack MN, Lehner R, Gupta MP, Michelakis ED, Padwal RS, Johnstone DE, Sharma AM, and Lopaschuk GD. Obesity-induced lysine acetylation increases cardiac fatty acid oxidation and impairs insulin signalling. Cardiovasc Res 103: 485–497, 2014.
14. Altmeyer M and Hottiger MO. Poly(ADP-ribose) polymerase 1 at the crossroad of metabolic stress and inflammation in aging. Aging (Albany NY) 1: 458–469, 2009.
15. Altmeyer M, Messner S, Hassa PO, Fey M, and Hottiger MO. Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites. Nucleic Acids Res 37: 3723–3738, 2009.
16. Anderson RM, Bitterman KJ, Wood JG, Medvedik O, and Sinclair DA. Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature 423: 181–185, 2003.
17. Andrabi SA, Umanah GKE, Chang C, Stevens DA, Karuppagounder SS, Gagne JP, Poirier GG, Dawson VL, and Dawson TM. Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proc Natl Acad Sci U S A 111: 10209–10214, 2014.
18. Ansari A, Rahman MS, Saha SK, Saikot FK, Deep A, and Kim KH. Function of the SIRT3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease. Aging Cell 16: 4–16, 2017.
19. ApSimon MM, Rawling JM, and Kirkland JB. Nicotinamide megadosing increases hepatic poly(ADP-ribose) levels in choline-deficient rats. J Nutr 125: 1826–1832, 1995.
20. Arpaia E, Benveniste P, Di Cristofano A, Gu Y, Dalal I, Kelly S, Hershfield M, Pandolfi PP, Roifman CM, and Cohen A. Mitochondrial basis for immune deficiency. Evidence from purine nucleoside phosphorylase-deficient mice. J Exp Med 191: 2197–2208, 2000.
21. Badawy AA. Pellagra and alcoholism: a biochemical perspective. Alcohol Alcohol 49: 238–250, 2014.
22. Badawy AA. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int J Tryptophan Res 10: 1178646917691938, 2017.
23. Ball HJ, Yuasa HJ, Austin CJ, Weiser S, and Hunt NH. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol 41: 467–471, 2009.
24. Balu M, Mazhar A, Hayakawa CK, Mittal R, Krasieva TB, Konig K, Venugopalan V, and Tromberg BJ. In vivo multiphoton NADH fluorescence reveals depth-dependent keratinocyte metabolism in human skin. Biophys J 104: 258–267, 2013.
25. Bansal A, Kwon ES, Conte D Jr., Liu H, Gilchrist MJ, MacNeil LT, and Tissenbaum HA. Transcriptional regulation of Caenorhabditis elegans FOXO/DAF-16 modulates lifespan. Longev Healthspan 3: 5, 2014.
26. Bartleman AP, Jacobs R, and Kirkland JB. Niacin supplementation decreases the incidence of alkylation-induced nonlymphocytic leukemia in Long-Evans rats. Nutr Cancer 60: 251–258, 2008.
27. Benavente CA and Jacobson EL. Niacin restriction upregulates NADPH oxidase and reactive oxygen species (ROS) in human keratinocytes. Free Radic Biol Med 44: 527–537, 2008.
28. Bender DA and McCreanor GM. Kynurenine hydroxylase: a potential rate-limiting enzyme in tryptophan metabolism. Biochem Soc Trans 13: 441–443, 1985.
29. Benfeitas R, Uhlen M, Nielsen J, and Mardinoglu A. New challenges to study heterogeneity in cancer redox metabolism. Front Cell Dev Biol 5: 65, 2017.
30. Beninger RJ, Colton AM, Ingles JL, Jhamandas K, and Boegman RJ. Picolinic acid blocks the neurotoxic but not the neuroexcitant properties of quinolinic acid in the rat brain: evidence from turning behaviour and tyrosine hydroxylase immunohistochemistry. Neuroscience 61: 603–612, 1994.
31. Berger F, Lau C, Dahlmann M, and Ziegler M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J Biol Chem 280: 36334–36341, 2005.
32. Berger F, Lau C, and Ziegler M. Regulation of poly(ADP-ribose) polymerase 1 activity by the phosphorylation state of the nuclear NAD biosynthetic enzyme NMN adenylyl transferase 1. Proc Natl Acad Sci U S A 104: 3765–3770, 2007.
33. Bhatia R and Calvo KC. The sequencing expression, purification, and steady-state kinetic analysis of quinolinate phosphoribosyl transferase from Escherichia coli. Arch Biochem Biophys 325: 270–278, 1996.
34. Birkmayer JG and Nadlinger K. Safety of stabilized, orally absorbable, reduced nicotinamide adenine dinucleotide (NADH): a 26-week oral tablet administration of ENADA/NADH for chronic toxicity study in rats. Drugs Exp Clin Res 28: 185–192, 2002.
35. Birkmayer JG, Vrecko C, Volc D, and Birkmayer W. Nicotinamide adenine dinucleotide (NADH)—a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta Neurol Scand Suppl 146: 32–35, 1993.
36. Blagosklonny MV. Hormesis does not make sense except in the light of TOR-driven aging. Aging (Albany NY) 3: 1051–1062, 2011.
37. Blum CA, Ellis JL, Loh C, Ng PY, Perni RB, and Stein RL. SIRT1 modulation as a novel approach to the treatment of diseases of aging. J Med Chem 54: 417–432, 2011.
38. Bogan KL and Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr 28: 115–130, 2008.
39. Borra MT, Smith BC, and Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280: 17187–17195, 2005.
40. Bouamama S, Merzouk H, Medjdoub A, Merzouk-Saidi A, and Merzouk SA. Effects of exogenous vitamins A, C, and E and NADH supplementation on proliferation, cytokines release, and cell redox status of lymphocytes from healthy aged subjects. Appl Physiol Nutr Metab 42: 579–587, 2017.
41. Boylston JA, Sun J, Chen Y, Gucek M, Sack MN, and Murphy E. Characterization of the cardiac succinylome and its role in ischemia-reperfusion injury. J Mol Cell Cardiol 88: 73–81, 2015.
42. Boyonoski AC, Spronck JC, Gallacher LM, Jacobs RM, Shah GM, Poirier GG, and Kirkland JB. Niacin deficiency decreases bone marrow poly(ADP-ribose) and the latency of ethylnitrosourea-induced carcinogenesis in rats. J Nutr 132: 108–114, 2002.
43. Boyonoski AC, Spronck JC, Jacobs RM, Shah GM, Poirier GG, and Kirkland JB. Pharmacological intakes of niacin increase bone marrow poly(ADP-ribose) and the latency of ethylnitrosourea-induced carcinogenesis in rats. J Nutr 132: 115–120, 2002.
44. Braidy N, Brew BJ, Inestrosa NC, Chung R, Sachdev P, and Guillemin GJ. Changes in Cathepsin D and Beclin-1 mRNA and protein expression by the excitotoxin quinolinic acid in human astrocytes and neurons. Metab Brain Dis 29: 873–883, 2014.
45. Braidy N and Grant R. Kynurenine pathway metabolism and neuroinflammatory disease. Neural Regen Res 12: 39–42, 2017.
46. Braidy N, Grant R, Adams S, Brew BJ, and Guillemin GJ. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res 16: 77–86, 2009.
47. Braidy N, Grant R, Adams S, and Guillemin GJ. Neuroprotective effects of naturally occurring polyphenols on quinolinic acid-induced excitotoxicity in human neurons. FEBS J 277: 368–382, 2010.
48. Braidy N, Grant R, Brew BJ, Adams S, Jayasena T, and Guillemin GJ. Effects of Kynurenine pathway metabolites on intracellular NAD synthesis and cell death in human primary astrocytes and neurons. Int J Tryptophan Res 2: 61–69, 2009.
49. Braidy N, Guillemin G, and Grant R. Promotion of cellular NAD(+) anabolism: therapeutic potential for oxidative stress in ageing and Alzheimer's disease. Neurotox Res 13: 173–184, 2008.
50. Braidy N, Guillemin GJ, and Grant R. Effects of Kynurenine pathway inhibition on NAD metabolism and cell viability in human primary astrocytes and neurons. Int J Tryptophan Res 4: 29–37, 2011.
51. Braidy N, Guillemin GJ, Mansour H, Chan-Ling T, Poljak A, and Grant R. Age related changes in NAD+ metabolism oxidative stress and Sirt1 activity in wistar rats. PLoS One 6: e19194, 2011.
52. Braidy N, Poljak A, Grant R, Jayasena T, Mansour H, Chan-Ling T, Guillemin GJ, Smythe G, and Sachdev P. Mapping NAD(+) metabolism in the brain of ageing Wistar rats: potential targets for influencing brain senescence. Biogerontology 15: 177–198, 2014.
53. Braidy N, Poljak A, Grant R, Jayasena T, Mansour H, Chan-Ling T, Smythe G, Sachdev P, and Guillemin GJ. Differential expression of sirtuins in the aging rat brain. Front Cell Neurosci 9: 167, 2015.
54. Brazill JM, Li C, Zhu Y, and Zhai RG. NMNAT: it's an NAD+ synthase … it's a chaperone … it's a neuroprotector. Curr Opin Genet Dev 44: 156–162, 2017.
55. Brousseau KM, Filley CM, Kaye K, Kiser JJ, Adler LE, and Connick E. Dementia with features of Alzheimer's disease and HIV-associated dementia in an elderly man with AIDS. AIDS 23: 1029–1031, 2009.
56. Brown KD, Maqsood S, Huang JY, Pan Y, Harkcom W, Li W, Sauve A, Verdin E, and Jaffrey SR. Activation of SIRT3 by the NAD(+) precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metab 20: 1059–1068, 2014.
57. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedrychowski MP, Gygi SP, Sinclair DA, Alt FW, and Greenberg ME. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303: 2011–2015, 2004.
58. Busse M, Hettler V, Fischer V, Mawrin C, Hartig R, Dobrowolny H, Bogerts B, Frodl T, and Busse S. Increased quinolinic acid in peripheral mononuclear cells in Alzheimer's dementia. Eur Arch Psychiatry Clin Neurosci 2017.
59. Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, Leo O, So A, and De Smedt T. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 3: e2267, 2008.
60. Bustamante S, Jayasena T, Richani D, Gilchrist RB, Wu LE, Sinclair DA, Sachdev P, and Braidy N. Quantifying the cellular NAD+ metabolome using a tandem liquid chromatography mass spectrometry approach. Metabolomics 14: 15, 2018.
61. Cadenas C, Franckenstein D, Schmidt M, Gehrmann M, Hermes M, Geppert B, Schormann W, Maccoux LJ, Schug M, Schumann A, Wilhelm C, Freis E, Ickstadt K, Rahnenfuhrer J, Baumbach JI, Sickmann A, and Hengstler JG. Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res 12: R44, 2010.
62. Calabrese EJ. Hormesis: a fundamental concept in biology. Microb Cell 1: 145–149, 2014.
63. Calabrese EJ and Mattson MP. How does hormesis impact biology, toxicology, and medicine? NPJ Aging Mech Dis 3: 13, 2017.
64. Calabrese EJ, Mattson MP, and Calabrese V. Resveratrol commonly displays hormesis: occurrence and biomedical significance. Hum Exp Toxicol 29: 980–1015, 2010.
65. Camacho-Pereira J, Tarrago MG, Chini CCS, Nin V, Escande C, Warner GM, Puranik AS, Schoon RA, Reid JM, Galina A, and Chini EN. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab 23: 1127–1139, 2016.
66. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P, and Auwerx J. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458: 1056–1060, 2009.
67. Canto C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, Fernandez-Marcos PJ, Yamamoto H, Andreux PA, Cettour-Rose P, Gademann K, Rinsch C, Schoonjans K, Sauve AA, and Auwerx J. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 15: 838–847, 2012.
68. Canto C, Menzies KJ, and Auwerx J. NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab 22: 31–53, 2015.
69. Cao W, Hong Y, Chen H, Wu F, Wei X, and Ying W. SIRT2 mediates NADH-induced increases in Nrf2, GCL, and glutathione by modulating Akt phosphorylation in PC12 cells. FEBS Lett 590: 2241–2255, 2016.
70. Casabona G, Sturiale L, L'Episcopo MR, Raciti G, Fazzio A, Sarpietro MG, Genazzani AA, Cambria A, and Nicoletti F. HPLC analysis of cyclic adenosine diphosphate ribose and adenosine diphosphate ribose: determination of NAD+ metabolites in hippocampal membranes. Ital J Biochem 44: 258–268, 1995.
71. Castellano-Gonzalez G, Pichaud N, Ballard JW, Bessede A, Marcal H, and Guillemin GJ. Epigallocatechin-3-gallate induces oxidative phosphorylation by activating cytochrome c oxidase in human cultured neurons and astrocytes. Oncotarget 7: 7426–7440, 2016.
72. Catz P, Shinn W, Kapetanovic IM, Kim H, Kim M, Jacobson EL, Jacobson MK, and Green CE. Simultaneous determination of myristyl nicotinate, nicotinic acid, and nicotinamide in rabbit plasma by liquid chromatography-tandem mass spectrometry using methyl ethyl ketone as a deproteinization solvent. J Chromatogr B Analyt Technol Biomed Life Sci 829: 123–135, 2005.
73. Chambers DA, Martin DW Jr., and Weinstein Y. The effect of cyclic nucleotides on purine biosynthesis and the induction of PRPP synthetase during lymphocyte activation. Cell 3: 375–380, 1974.
74. Chapman MJ, Le Goff W, Guerin M, and Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 31: 149–164, 2010.
75. Chaudhuri RN and Chakravarti H. An outbreak of pellegra syndrome in a rural area of Bengal. Ind Med Gaz 82: 657–660, 1947.
76. Chini EN. CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions. Curr Pharm Des 15: 57–63, 2009.
77. This reference has been deleted.
78. Clementi E and Nisoli E. Nitric oxide and mitochondrial biogenesis: a key to long-term regulation of cellular metabolism. Comp Biochem Physiol A Mol Integr Physiol 142: 102–110, 2005.
79. Cockhill J, Jhamandas K, Boegman RJ, and Beninger RJ. Action of picolinic acid and structurally related pyridine carboxylic acids on quinolinic acid-induced cortical cholinergic damage. Brain Res 599: 57–63, 1992.
80. Coleman MP and Freeman MR. Wallerian degeneration, wld(s), and nmnat. Annu Rev Neurosci 33: 245–267, 2010.
81. Collins PB and Chaykin S. The management of nicotinamide and nicotinic acid in the mouse. J Biol Chem 247: 778–783, 1972.
82. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW, and Weindruch R. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 325: 201–204, 2009.
83. Colman RJ, Beasley TM, Kemnitz JW, Johnson SC, Weindruch R, and Anderson RM. Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys. Nat Commun 5: 3557, 2014.
84. Cooper DL, Murrell DE, Roane DS, and Harirforoosh S. Effects of formulation design on niacin therapeutics: mechanism of action, metabolism, and drug delivery. Int J Pharm 490: 55–64, 2015.
85. Dantzer F, Ame JC, Schreiber V, Nakamura J, Menissier-de Murcia J, and de Murcia G. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair. Methods Enzymol 409: 493–510, 2006.
86. Dasgupta B and Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A 104: 7217–7222, 2007.
87. de Picciotto NE, Gano LB, Johnson LC, Martens CR, Sindler AL, Mills KF, Imai S, and Seals DR. Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice. Aging Cell 15: 522–530, 2016.
88. Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, and Marcotulli E. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD(+) levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging Mech Dis 3: 17, 2017.
89. Di Lisa F and Ziegler M. Pathophysiological relevance of mitochondria in NAD(+) metabolism. FEBS Lett 492: 4–8, 2001.
90. Di Stefano M and Conforti L. Diversification of NAD biological role: the importance of location. FEBS J 280: 4711–4728, 2013.
91. Diamond MP, Fletcher NM, Neubauer BR, Saed MG, H M AS, and Saed GM. Hypoxia-induced genotype switch in nicotinamide adenine dinucleotide phosphate (NADPH) oxidase through the up-regulation of cytidine deaminase regulates postoperative adhesion development. J Minim Invasive Gynecol 22: S159, 2015.
92. Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD, and Garcia JA. Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science 324: 1289–1293, 2009.
93. Dragovic J, Kim SH, Brown SL, and Kim JH. Nicotinamide pharmacokinetics in patients. Radiother Oncol 36: 225–228, 1995.
94. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, and Brownlee M. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112: 1049–1057, 2003.
95. Duarte-Pereira S, Pereira-Castro I, Silva SS, Correia MG, Neto C, da Costa LT, Amorim A, and Silva RM. Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors. Oncotarget 7: 1973–1983, 2016.
96. Duley JA, Christodoulou J, and de Brouwer AP. The PRPP synthetase spectrum: what does it demonstrate about nucleotide syndromes? Nucleosides Nucleotides Nucleic Acids 30: 1129–1139, 2011.
97. Easlon E, Tsang F, Skinner C, Wang C, and Lin SJ. The malate-aspartate NADH shuttle components are novel metabolic longevity regulators required for calorie restriction-mediated life span extension in yeast. Genes Dev 22: 931–944, 2008.
98. Easton T, Richardson AJ, Hall AD, Kidane L, Das I, and Puri BK. The niacin flush test as an index of fatty acid deficiency in schizophrenia. Schizophr Res 36: 307–308, 1999.
99. Elvehjem CA, Madden RJ, Strong FM, and Wolley DW. The isolation and identification of the anti-black tongue factor. 1937. J Biol Chem 277: e22, 2002.
100. Elvehjem CA, Madden RJ, Strong FM, and Woolley DW. The isolation and identification of the anti-black tongue factor. Nutr Rev 32: 48–50, 1974.
101. Fan J, Krautkramer KA, Feldman JL, and Denu JM. Metabolic regulation of histone post-translational modifications. ACS Chem Biol 10: 95–108, 2015.
102. Fang EF, Lautrup S, Hou Y, Demarest TG, Croteau DL, Mattson MP, and Bohr VA. NAD(+) in aging: molecular mechanisms and translational implications. Trends Mol Med 23: 899–916, 2017.
103. Fatokun AA, Hunt NH, and Ball HJ. Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease. Amino Acids 45: 1319–1329, 2013.
104. Fazio F, Carrizzo A, Lionetto L, Damato A, Capocci L, Ambrosio M, Battaglia G, Bruno V, Madonna M, Simmaco M, Nicoletti F, and Vecchione C. Vasorelaxing action of the kynurenine metabolite, xanthurenic acid: the missing link in endotoxin-induced hypotension? Front Pharmacol 8: 214, 2017.
105. Fedele G, Frasca L, Palazzo R, Ferrero E, Malavasi F, and Ausiello CM. CD38 is expressed on human mature monocyte-derived dendritic cells and is functionally involved in CD83 expression and IL-12 induction. Eur J Immunol 34: 1342–1350, 2004.
106. Fernandez-Pol JA. Transition metal ions induce cell growth in NRK cells synchronized in G1 by picolinic acid. Biochem Biophys Res Commun 76: 413–419, 1976.
107. Fu CS, Swendseid ME, Jacob RA, and McKee RW. Biochemical markers for assessment of niacin status in young men: levels of erythrocyte niacin coenzymes and plasma tryptophan. J Nutr 119: 1949–1955, 1989.
108. Fukui M, Choi HJ, and Zhu BT. Mechanism for the protective effect of resveratrol against oxidative stress-induced neuronal death. Free Radic Biol Med 49: 800–813, 2010.
109. Fukunaga M, Yamamoto Y, Kawasoe M, Arioka Y, Murakami Y, Hoshi M, and Saito K. Studies on tissue and cellular distribution of indoleamine 2,3-dioxygenase 2: the absence of IDO1 upregulates IDO2 expression in the epididymis. J Histochem Cytochem 60: 854–860, 2012.
110. Fulco M, Cen Y, Zhao P, Hoffman EP, McBurney MW, Sauve AA, and Sartorelli V. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell 14: 661–673, 2008.
111. Gaertner FH and Shetty AS. Kynureninase-type enzymes and the evolution of the aerobic tryptophan-to-nicotinamide adenine dinucleotide pathway. Biochim Biophys Acta 482: 453–460, 1977.
112. Galassi L, Di Stefano M, Brunetti L, Orsomando G, Amici A, Ruggieri S, and Magni G. Characterization of human nicotinate phosphoribosyltransferase: kinetic studies, structure prediction and functional analysis by site-directed mutagenesis. Biochimie 94: 300–309, 2012.
113. Gale EA, Bingley PJ, Emmett CL, and Collier T; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 363: 925–931, 2004.
114. Ganji SH, Qin S, Zhang L, Kamanna VS, and Kashyap ML. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 202: 68–75, 2009.
115. Gensler HL. Prevention of photoimmunosuppression and photocarcinogenesis by topical nicotinamide. Nutr Cancer 29: 157–162, 1997.
116. Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim SH, Mostoslavsky R, Alt FW, Wu Z, and Puigserver P. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J 26: 1913–1923, 2007.
117. Gillman J and Gillman T. Malnutrition and pellegra in South Africa. Nutr Rev 5: 353–355, 1947.
118. Godoy JA, Rios JA, Zolezzi JM, Braidy N, and Inestrosa NC. Signaling pathway cross talk in Alzheimer's disease. Cell Commun Signal 12: 23, 2014.
119. Godoy JA, Zolezzi JM, Braidy N, and Inestrosa NC. Role of Sirt1 during the ageing process: relevance to protection of synapses in the brain. Mol Neurobiol 50: 744–756, 2014.
120. This reference has been deleted.
121. Goldberger J. The etiology of pellagra. 1914. Public Health Rep 121(Suppl 1): 77–79; discussion 76, 2006.
122. Gonzalez Esquivel D, Ramirez-Ortega D, Pineda B, Castro N, Rios C, and Perez de la Cruz V. Kynurenine pathway metabolites and enzymes involved in redox reactions. Neuropharmacology 112: 331–345, 2017.
123. Gorrini C, Harris IS, and Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12: 931–947, 2013.
124. Gospe SM Jr., Olin KL, and Keen CL. Reduced GABA synthesis in pyridoxine-dependent seizures. Lancet 343: 1133–1134, 1994.
125. Goto T, Matsuo N, and Takahashi T. CSF glutamate/GABA concentrations in pyridoxine-dependent seizures: etiology of pyridoxine-dependent seizures and the mechanisms of pyridoxine action in seizure control. Brain Dev 23: 24–29, 2001.
126. Gougeon L, Payette H, Morais JA, Gaudreau P, Shatenstein B, and Gray-Donald K. Intakes of folate, vitamin B6 and B12 and risk of depression in community-dwelling older adults: the Quebec Longitudinal Study on Nutrition and Aging. Eur J Clin Nutr 70: 380–385, 2016.
127. Grant RS and Kapoor V. Murine glial cells regenerate NAD, after peroxide-induced depletion, using either nicotinic acid, nicotinamide, or quinolinic acid as substrates. J Neurochem 70: 1759–1763, 1998.
128. Grant RS, Passey R, Matanovic G, Smythe G, and Kapoor V. Evidence for increased de novo synthesis of NAD in immune-activated RAW264.7 macrophages: a self-protective mechanism? Arch Biochem Biophys 372: 1–7, 1999.
129. Guan X, Lin P, Knoll E, and Chakrabarti R. Mechanism of inhibition of the human sirtuin enzyme SIRT3 by nicotinamide: computational and experimental studies. PLoS One 9: e107729, 2014.
130. Guan XH, Hong X, Zhao N, Liu XH, Xiao YF, Chen TT, Deng LB, Wang XL, Wang JB, Ji GJ, Fu M, Deng KY, and Xin HB. CD38 promotes angiotensin II-induced cardiac hypertrophy. J Cell Mol Med 21: 1492–1502, 2017.
131. Guan XH, Liu XH, Hong X, Zhao N, Xiao YF, Wang LF, Tang L, Jiang K, Qian YS, Deng KY, Ji GJ, Fu MG, and Xin HB. CD38 deficiency protects the heart from ischemia/reperfusion injury through activating SIRT1/FOXOs-mediated antioxidative stress pathway. Oxid Med Cell Longev 2016: 7410257, 2016.
132. Guillemin GJ and Brew BJ. Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep 7: 199–206, 2002.
133. Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol 18: 415–420, 2007.
134. Ha C, Miller LT, and Kerkvliet NI. The effect of vitamin B6 deficiency on cytotoxic immune responses of T cells, antibodies, and natural killer cells, and phagocytosis by macrophages. Cell Immunol 85: 318–329, 1984.
135. Haag F, Adriouch S, Brass A, Jung C, Moller S, Scheuplein F, Bannas P, Seman M, and Koch-Nolte F. Extracellular NAD and ATP: partners in immune cell modulation. Purinergic Signal 3: 71–81, 2007.
136. Haigis MC, Mostoslavsky R, Haigis KM, Fahie K, Christodoulou DC, Murphy AJ, Valenzuela DM, Yancopoulos GD, Karow M, Blander G, Wolberger C, Prolla TA, Weindruch R, Alt FW, and Guarente L. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell 126: 941–954, 2006.
137. Hallows WC, Yu W, Smith BC, Devries MK, Ellinger JJ, Someya S, Shortreed MR, Prolla T, Markley JL, Smith LM, Zhao S, Guan KL, and Denu JM. Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction. Mol Cell 41: 139–149, 2011.
138. Hammen PK, Allali-Hassani A, Hallenga K, Hurley TD, and Weiner H. Multiple conformations of NAD and NADH when bound to human cytosolic and mitochondrial aldehyde dehydrogenase. Biochemistry 41: 7156–7168, 2002.
139. Han MK, Song EK, Guo Y, Ou X, Mantel C, and Broxmeyer HE. SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell 2: 241–251, 2008.
140. Han Q, Robinson H, and Li J. Biochemical identification and crystal structure of kynurenine formamidase from Drosophila melanogaster. Biochem J 446: 253–260, 2012.
141. Hansson O. Tryptophan load test and pyridoxine treatment in epileptic children. Acta Neurol Scand 43(Suppl 31):65, 1967.
142. Hara N, Yamada K, Shibata T, Osago H, Hashimoto T, and Tsuchiya M. Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. J Biol Chem 282: 24574–24582, 2007.
143. Harkcom WT, Ghosh AK, Sung MS, Matov A, Brown KD, Giannakakou P, and Jaffrey SR. NAD+ and SIRT3 control microtubule dynamics and reduce susceptibility to antimicrotubule agents. Proc Natl Acad Sci U S A 111: E2443–E2452, 2014.
144. Hasegawa K, Wakino S, Yoshioka K, Tatematsu S, Hara Y, Minakuchi H, Washida N, Tokuyama H, Hayashi K, and Itoh H. Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression. Biochem Biophys Res Commun 372: 51–56, 2008.
145. Hassa PO, Haenni SS, Elser M, and Hottiger MO. Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? Microbiol Mol Biol Rev 70: 789–829, 2006.
146. He W, Wang Y, Zhang MZ, You L, Davis LS, Fan H, Yang HC, Fogo AB, Zent R, Harris RC, Breyer MD, and Hao CM. Sirt1 activation protects the mouse renal medulla from oxidative injury. J Clin Invest 120: 1056–1068, 2010.
147. Hegab Z, Mohamed TMA, Stafford N, Mamas M, Cartwright EJ, and Oceandy D. Advanced glycation end products reduce the calcium transient in cardiomyocytes by increasing production of reactive oxygen species and nitric oxide. FEBS Open Bio 7: 1672–1685, 2017.
148. Hegyi J, Schwartz RA, and Hegyi V. Pellagra: dermatitis, dementia, and diarrhea. Int J Dermatol 43: 1–5, 2004.
149. Herrero-Yraola A, Bakhit SM, Franke P, Weise C, Schweiger M, Jorcke D, and Ziegler M. Regulation of glutamate dehydrogenase by reversible ADP-ribosylation in mitochondria. EMBO J 20: 2404–2412, 2001.
150. Hershberger KA, Martin AS, and Hirschey MD. Role of NAD(+) and mitochondrial sirtuins in cardiac and renal diseases. Nat Rev Nephrol 13: 213–225, 2017.
151. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, Grueter CA, Harris C, Biddinger S, Ilkayeva OR, Stevens RD, Li Y, Saha AK, Ruderman NB, Bain JR, Newgard CB, Farese RV Jr., Alt FW, Kahn CR, and Verdin E. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 464: 121–125, 2010.
152. Hong S, Moreno-Navarrete JM, Wei X, Kikukawa Y, Tzameli I, Prasad D, Lee Y, Asara JM, Fernandez-Real JM, Maratos-Flier E, and Pissios P. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat Med 21: 887–894, 2015.
153. Hong SJ, Dawson TM, and Dawson VL. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci 25: 259–264, 2004.
154. Hopkins FG and Cole SW. A contribution to the chemistry of proteids: Part I. A preliminary study of a hitherto undescribed product of tryptic digestion. J Physiol 27: 418–428, 1901.
155. Horenstein AL, Sizzano F, Lusso R, Besso FG, Ferrero E, Deaglio S, Corno F, and Malavasi F. CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus. Mol Med 15: 76–84, 2009.
156. Horton JL, Martin OJ, Lai L, Riley NM, Richards AL, Vega RB, Leone TC, Pagliarini DJ, Muoio DM, Bedi KC Jr., Margulies KB, Coon JJ, and Kelly DP. Mitochondrial protein hyperacetylation in the failing heart. JCI Insight 2: e84897, 2016.
157. Houtkooper RH, Canto C, Wanders RJ, and Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 31: 194–223, 2010.
158. Hunt GE, Van Nieuwenhuijzen PS, Chan-Ling T, and McGregor IS. “When an old rat smells a cat”: a decline in defense-related, but not accessory olfactory, Fos expression in aged rats. Neurobiol Aging 32: 737–749, 2011.
159. Hwang ES and Song SB. Nicotinamide is an inhibitor of SIRT1 in vitro, but can be a stimulator in cells. Cell Mol Life Sci 74: 3347–3362, 2017.
160. Imai S and Yoshino J. The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing. Diabetes Obes Metab 15(Suppl 3): 26–33, 2013.
161. Ishidoh K, Kamemura N, Imagawa T, Oda M, Sakurai J, and Katunuma N. Quinolinate phosphoribosyl transferase, a key enzyme in de novo NAD(+) synthesis, suppresses spontaneous cell death by inhibiting overproduction of active-caspase-3. Biochim Biophys Acta 1803: 527–533, 2010.
162. Iwai K and Taguchi H. Distribution of quinolinate phosphoribosyl-transferase in animals, plants and microorganisms. J Nutr Sci Vitaminol (Tokyo) 19: 491–499, 1973.
163. Jackson TM, Rawling JM, Roebuck BD, and Kirkland JB. Large supplements of nicotinic acid and nicotinamide increase tissue NAD+ and poly(ADP-ribose) levels but do not affect diethylnitrosamine-induced altered hepatic foci in Fischer-344 rats. J Nutr 125: 1455–1461, 1995.
164. Jacob RA, Swendseid ME, McKee RW, Fu CS, and Clemens RA. Biochemical markers for assessment of niacin status in young men: urinary and blood levels of niacin metabolites. J Nutr 119: 591–598, 1989.
165. Jayaram HN, Kusumanchi P, and Yalowitz JA. NMNAT expression and its relation to NAD metabolism. Curr Med Chem 18: 1962–1972, 2011.
166. Jin D, Liu HX, Hirai H, Torashima T, Nagai T, Lopatina O, Shnayder NA, Yamada K, Noda M, Seike T, Fujita K, Takasawa S, Yokoyama S, Koizumi K, Shiraishi Y, Tanaka S, Hashii M, Yoshihara T, Higashida K, Islam MS, Yamada N, Hayashi K, Noguchi N, Kato I, Okamoto H, Matsushima A, Salmina A, Munesue T, Shimizu N, Mochida S, Asano M, and Higashida H. CD38 is critical for social behaviour by regulating oxytocin secretion. Nature 446: 41–45, 2007.
167. Kaanders JH, Stratford MR, Liefers J, Dennis MF, van der Kogel AJ, van Daal WA, and Rojas A. Administration of nicotinamide during a five- to seven-week course of radiotherapy: pharmacokinetics, tolerance, and compliance. Radiother Oncol 43: 67–73, 1997.
168. Kalikin L and Calvo KC. Inhibition of quinolinate phosphoribosyl transferase by pyridine analogs of quinolinic acid. Biochem Biophys Res Commun 152: 559–564, 1988.
169. Kamanna VS and Kashyap ML. Mechanism of action of niacin on lipoprotein metabolism. Curr Atheroscler Rep 2: 36–46, 2000.
170. Kamanna VS and Kashyap ML. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am J Cardiol 100: S53–S61, 2007.
171. Kamanna VS and Kashyap ML. Mechanism of action of niacin. Am J Cardiol 101: 20B–26B, 2008.
172. Kang L and Da Vanzo JP. Is the tryptophan load test a valid index for a chemically-induced vitamin B6 deficiency? Proc Soc Exp Biol Med 123: 340–343, 1966.
173. Kang-Lee YA, McKee RW, Wright SM, Swendseid ME, Jenden DJ, and Jope RS. Metabolic effects of nicotinamide administration in rats. J Nutr 113: 215–221, 1983.
174. Karamanlidis G, Lee CF, Garcia-Menendez L, Kolwicz SC Jr., Suthammarak W, Gong G, Sedensky MM, Morgan PG, Wang W, and Tian R. Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metab 18: 239–250, 2013.
175. Khan NA, Khan I, Abid SMA, Zaib S, Ibrar A, Andleeb H, Hameed S, and Iqbal J. Quinolinic carboxylic acid derivatives as potential multi-target compounds for neurodegeneration: monoamine oxidase and cholinesterase inhibition. Med Chem 14: 74–85, 2018.
176. Khan S, Pandey SS, Jyotshna, Shanker K, Khan F, and Rahman LU. Cloning and functional characterization of quinolinic acid phosphoribosyl transferase (QPT) gene of Nicotiana tabacum. Physiol Plant 160: 253–265, 2017.
177. Kimura N, Fukuwatari T, Sasaki R, and Shibata K. Comparison of metabolic fates of nicotinamide, NAD+ and NADH administered orally and intraperitoneally; characterization of oral NADH. J Nutr Sci Vitaminol (Tokyo) 52: 142–148, 2006.
178. Kirkland JB. Niacin status and treatment-related leukemogenesis. Mol Cancer Ther 8: 725–732, 2009.
179. Kirkland JB. Niacin status impacts chromatin structure. J Nutr 139: 2397–2401, 2009.
180. Kirkland JB. Niacin requirements for genomic stability. Mutat Res 733: 14–20, 2012.
181. Kirkland JB. Niacin status and genomic instability in bone marrow cells; mechanisms favoring the progression of leukemogenesis. Subcell Biochem 56: 21–36, 2012.
182. Kitaoka Y, Munemasa Y, Kojima K, Hirano A, Ueno S, and Takagi H. Axonal protection by Nmnat3 overexpression with involvement of autophagy in optic nerve degeneration. Cell Death Dis 4: e860, 2013.
183. Kitay BM, McCormack R, Wang Y, Tsoulfas P, and Zhai RG. Mislocalization of neuronal mitochondria reveals regulation of Wallerian degeneration and NMNAT/WLD(S)-mediated axon protection independent of axonal mitochondria. Hum Mol Genet 22: 1601–1614, 2013.
184. Komrower GM, Wilson V, Clamp JR, and Westall RG. Hydroxykynureninuria: a case of abnormal tryptophan metabolism probably due to a deficiency of kynureninase. Arch Dis Child 39: 250–256, 1964.
185. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH, and Burgering BM. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419: 316–321, 2002.
186. Kourtzidis IA, Stoupas AT, Gioris IS, Veskoukis AS, Margaritelis NV, Tsantarliotou M, Taitzoglou I, Vrabas IS, Paschalis V, Kyparos A, and Nikolaidis MG. The NAD(+) precursor nicotinamide riboside decreases exercise performance in rats. J Int Soc Sports Nutr 13: 32, 2016.
187. Koyama T, Kume S, Koya D, Araki S, Isshiki K, Chin-Kanasaki M, Sugimoto T, Haneda M, Sugaya T, Kashiwagi A, Maegawa H, and Uzu T. SIRT3 attenuates palmitate-induced ROS production and inflammation in proximal tubular cells. Free Radic Biol Med 51: 1258–1267, 2011.
188. Krieger I and Statter M. Tryptophan deficiency and picolinic acid: effect on zinc metabolism and clinical manifestations of pellagra. Am J Clin Nutr 46: 511–517, 1987.
189. Krishnaswamy K and Bapurao S. Effect of leucine at different levels of pyridoxine on hepatic quinolinate phosphoribosyl transferase (EC 2.4.2.19) and leucine aminotransferase (EC 2.6.1.6) in rats. Br J Nutr 39: 61–64, 1978.
190. Kulikova V, Shabalin K, Nerinovski K, Dolle C, Niere M, Yakimov A, Redpath P, Khodorkovskiy M, Migaud ME, Ziegler M, and Nikiforov A. Generation, release, and uptake of the NAD precursor nicotinic acid riboside by human cells. J Biol Chem 290: 27124–27137, 2015.
191. Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Isono M, Isshiki K, Uzu T, Kashiwagi A, and Koya D. Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation. Free Radic Biol Med 40: 2175–2182, 2006.
192. Lan F, Cacicedo JM, Ruderman N, and Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem 283: 27628–27635, 2008.
193. Lau C, Niere M, and Ziegler M. The NMN/NaMN adenylyltransferase (NMNAT) protein family. Front Biosci (Landmark Ed) 14: 410–431, 2009.
194. Lee HJ, Hong YS, Jun W, and Yang SJ. Nicotinamide riboside ameliorates hepatic metaflammation by modulating NLRP3 inflammasome in a rodent model of type 2 diabetes. J Med Food 18: 1207–1213, 2015.
195. Lee MC, Ting KK, Adams S, Brew BJ, Chung R, and Guillemin GJ. Characterisation of the expression of NMDA receptors in human astrocytes. PLoS One 5: e14123, 2010.
196. Lehmann S, Costa AC, Celardo I, Loh SH, and Martins LM. PARP mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson's disease. Cell Death Dis 7: e2166, 2016.
197. Li D, Tian YJ, Guo J, Sun WP, Lun YZ, Guo M, Luo N, Cao Y, Cao JM, Gong XJ, and Zhou SS. Nicotinamide supplementation induces detrimental metabolic and epigenetic changes in developing rats. Br J Nutr 110: 2156–2164, 2013.
198. Li F, He X, Ye D, Lin Y, Yu H, Yao C, Huang L, Zhang J, Wang F, Xu S, Wu X, Liu L, Yang C, Shi J, He X, Liu J, Qu Y, Guo F, Zhao J, Xu W, and Zhao S. NADP(+)-IDH mutations promote hypersuccinylation that impairs mitochondria respiration and induces apoptosis resistance. Mol Cell 60: 661–675, 2015.
199. Li X, Zhang S, Blander G, Tse JG, Krieger M, and Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell 28: 91–106, 2007.
200. Lim JH, Lee YM, Chun YS, Chen J, Kim JE, and Park JW. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. Mol Cell 38: 864–878, 2010.
201. Lischke T, Heesch K, Schumacher V, Schneider M, Haag F, Koch-Nolte F, and Mittrucker HW. CD38 controls the innate immune response against Listeria monocytogenes. Infect Immun 81: 4091–4099, 2013.
202. Liu B, Che W, Xue J, Zheng C, Tang K, Zhang J, Wen J, and Xu Y. SIRT4 prevents hypoxia-induced apoptosis in H9c2 cardiomyoblast cells. Cell Physiol Biochem 32: 655–662, 2013.
203. Liu D, Gharavi R, Pitta M, Gleichmann M, and Mattson MP. Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons. Neuromolecular Med 11: 28–42, 2009.
204. Liu ZX, Azhipa O, Okamoto S, Govindarajan S, and Dennert G. Extracellular nicotinamide adenine dinucleotide induces T cell apoptosis in vivo and in vitro. J Immunol 167: 4942–4947, 2001.
205. Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, Mostoslavsky R, Kim J, Yancopoulos G, Valenzuela D, Murphy A, Yang Y, Chen Y, Hirschey MD, Bronson RT, Haigis M, Guarente LP, Farese RV Jr., Weissman S, Verdin E, and Schwer B. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol 27: 8807–8814, 2007.
206. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, and Kroemer G. The hallmarks of aging. Cell 153: 1194–1217, 2013.
207. Lu Z, Xu X, Hu X, Fassett J, Zhu G, Tao Y, Li J, Huang Y, Zhang P, Zhao B, and Chen Y. PGC-1 alpha regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload. Antioxid Redox Signal 13: 1011–1022, 2010.
208. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, and Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137–148, 2001.
209. Luo YX, Tang X, An XZ, Xie XM, Chen XF, Zhao X, Hao DL, Chen HZ, and Liu DP. SIRT4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity. Eur Heart J 38: 1389–1398, 2017.
210. Lynn EG, McLeod CJ, Gordon JP, Bao JJ, and Sack MN. SIRT2 is a negative regulator of anoxia-reoxygenation tolerance via regulation of 14-3-3 zeta and BAD in H9c2 cells. FEBS Lett 582: 2857–2862, 2008.
211. Mack TG, Reiner M, Beirowski B, Mi W, Emanuelli M, Wagner D, Thomson D, Gillingwater T, Court F, Conforti L, Fernando FS, Tarlton A, Andressen C, Addicks K, Magni G, Ribchester RR, Perry VH, and Coleman MP. Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci 4: 1199–1206, 2001.
212. Magni G, Amici A, Emanuelli M, Orsomando G, Raffaelli N, and Ruggieri S. Enzymology of NAD+ homeostasis in man. Cell Mol Life Sci 61: 19–34, 2004.
213. Magni G, Amici A, Emanuelli M, Raffaelli N, and Ruggieri S. Enzymology of NAD+ synthesis. Adv Enzymol Relat Areas Mol Biol 73: 135–182, xi, 1999.
214. Magni G, Amici A, and Orsomando G. The enzymology of cytosolic pyrimidine 5′-nucleotidases: functional analysis and physiopathological implications. Curr Med Chem 20: 4304–4316, 2013.
215. Maier KG. Nicotinamide adenine dinucleotide phosphate oxidase and diabetes: vascular implications. Vasc Endovascular Surg 42: 305–313, 2008.
216. Majmundar AJ, Wong WJ, and Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 40: 294–309, 2010.
217. Maltos AL, Portari GV, Moraes GV, Monteiro MC, Vannucchi H, and da Cunha DF. Niacin metabolism and indoleamine 2,3-dioxygenase activation in malnourished patients with flaky paint dermatosis. Nutrition 31: 890–892, 2015.
218. Mansour H, McColm JR, Cole L, Weible M 2nd, Korlimbinis A, and Chan-Ling T. Connexin 30 expression and frequency of connexin heterogeneity in astrocyte gap junction plaques increase with age in the rat retina. PLoS One 8: e57038, 2013.
219. Marohnic CC, Bewley MC, and Barber MJ. Engineering and characterization of a NADPH-utilizing cytochrome b5 reductase. Biochemistry 42: 11170–11182, 2003.
220. Martire S, Fuso A, Mosca L, Forte E, Correani V, Fontana M, Scarpa S, Maras B, and d'Erme M. Bioenergetic impairment in animal and cellular models of Alzheimer's disease: PARP-1 inhibition rescues metabolic dysfunctions. J Alzheimers Dis 54: 307–324, 2016.
221. Martire S, Mosca L, and d'Erme M. PARP-1 involvement in neurodegeneration: a focus on Alzheimer's and Parkinson's diseases. Mech Ageing Dev 146–148: 53–64, 2015.
222. Marzetti E, Wohlgemuth SE, Aulisa AG, Bernabei R, Pahor M, and Leeuwenburgh C. Calorie restriction for optimal cardiovascular aging: the weight of evidence. Curr Cardiovasc Risk Rep 4: 340–346, 2010.
223. Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, and Guillemin GJ. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One 7: e42357, 2012.
224. Massudi H, Grant R, Guillemin GJ, and Braidy N. NAD+ metabolism and oxidative stress: the golden nucleotide on a crown of thorns. Redox Rep 17: 28–46, 2012.
225. Mattagajasingh I, Kim CS, Naqvi A, Yamamori T, Hoffman TA, Jung SB, DeRicco J, Kasuno K, and Irani K. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 104: 14855–14860, 2007.
226. Mattison JA, Colman RJ, Beasley TM, Allison DB, Kemnitz JW, Roth GS, Ingram DK, Weindruch R, de Cabo R, and Anderson RM. Caloric restriction improves health and survival of rhesus monkeys. Nat Commun 8: 14063, 2017.
227. Mattison JA, Roth GS, Beasley TM, Tilmont EM, Handy AM, Herbert RL, Longo DL, Allison DB, Young JE, Bryant M, Barnard D, Ward WF, Qi W, Ingram DK, and de Cabo R. Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study. Nature 489: 318–321, 2012.
228. McClure JM, Wierman MB, Maqani N, and Smith JS. Isonicotinamide enhances Sir2 protein-mediated silencing and longevity in yeast by raising intracellular NAD+ concentration. J Biol Chem 287: 20957–20966, 2012.
229. McLin JP, Thompson LM, and Steward O. Differential susceptibility to striatal neurodegeneration induced by quinolinic acid and kainate in inbred, outbred and hybrid mouse strains. Eur J Neurosci 24: 3134–3140, 2006.
230. Mehler AH. Formation of picolinic and quinolinic acids following enzymatic oxidation of 3-hydroxyanthranilic acid. J Biol Chem 218: 241–254, 1956.
231. Menon RM, Adams MH, Gonzalez MA, Tolbert DS, Leu JH, and Cefali EA. Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. Int J Clin Pharmacol Ther 45: 448–454, 2007.
232. Menon RM, Gonzalez MA, Adams MH, Tolbert DS, Leu JH, and Cefali EA. Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites. J Clin Pharmacol 47: 681–688, 2007.
233. Mesripour A, Hajhashemi V, and Kuchak A. Effect of concomitant administration of three different antidepressants with vitamin B6 on depression and obsessive compulsive disorder in mice models. Res Pharm Sci 12: 46–52, 2017.
234. Monfrecola G, Gaudiello F, Cirillo T, Fabbrocini G, Balato A, and Lembo S. Nicotinamide downregulates gene expression of interleukin-6, interleukin-10, monocyte chemoattractant protein-1, and tumour necrosis factor-alpha gene expression in HaCaT keratinocytes after ultraviolet B irradiation. Clin Exp Dermatol 38: 185–188, 2013.
235. Moresco RM, Lavazza T, Belloli S, Lecchi M, Pezzola A, Todde S, Matarrese M, Carpinelli A, Turolla E, Zimarino V, Popoli P, Malgaroli A, and Fazio F. Quinolinic acid induced neurodegeneration in the striatum: a combined in vivo and in vitro analysis of receptor changes and microglia activation. Eur J Nucl Med Mol Imaging 35: 704–715, 2008.
236. Mori V, Amici A, Mazzola F, Di Stefano M, Conforti L, Magni G, Ruggieri S, Raffaelli N, and Orsomando G. Metabolic profiling of alternative NAD biosynthetic routes in mouse tissues. PLoS One 9: e113939, 2014.
237. Morigi M, Perico L, Rota C, Longaretti L, Conti S, Rottoli D, Novelli R, Remuzzi G, and Benigni A. Sirtuin 3-dependent mitochondrial dynamic improvements protect against acute kidney injury. J Clin Invest 125: 715–726, 2015.
238. Moroni F, Carpenedo R, and Chiarugi A. Kynurenine hydroxylase and kynureninase inhibitors as tools to study the role of kynurenine metabolites in the central nervous system. Adv Exp Med Biol 398: 203–210, 1996.
239. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, Liu P, Mostoslavsky G, Franco S, Murphy MM, Mills KD, Patel P, Hsu JT, Hong AL, Ford E, Cheng HL, Kennedy C, Nunez N, Bronson R, Frendewey D, Auerbach W, Valenzuela D, Karow M, Hottiger MO, Hursting S, Barrett JC, Guarente L, Mulligan R, Demple B, Yancopoulos GD, and Alt FW. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 124: 315–329, 2006.
240. Myint AM and Kim YK. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 48: 304–313, 2014.
241. Nahalkova J. Novel protein-protein interactions of TPPII, p53, and SIRT7. Mol Cell Biochem 409: 13–22, 2015.
242. Nakagawa T, Lomb DJ, Haigis MC, and Guarente L. SIRT5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 137: 560–570, 2009.
243. Nakahata Y and Bessho Y. The circadian NAD+ metabolism: impact on chromatin remodeling and aging. Biomed Res Int 2016: 3208429, 2016.
244. Nakamichi R, Miranda EP, Lobo SM, Tristao VR, Dalboni MA, Quinto BM, and Batista MC. Action of nicotinic acid on the reversion of hypoxic-inflammatory link on 3T3-L1 adipocytes. Lipids Health Dis 15: 91, 2016.
245. Nematollahi A, Sun G, Jayawickrama GS, and Church WB. Kynurenine aminotransferase isozyme inhibitors: a review. Int J Mol Sci 17: 946, 2016.
246. Nemoto S, Fergusson MM, and Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol Chem 280: 16456–16460, 2005.
247. Niere M, Kernstock S, Koch-Nolte F, and Ziegler M. Functional localization of two poly(ADP-ribose)-degrading enzymes to the mitochondrial matrix. Mol Cell Biol 28: 814–824, 2008.
248. Nishida Y, Rardin MJ, Carrico C, He W, Sahu AK, Gut P, Najjar R, Fitch M, Hellerstein M, Gibson BW, and Verdin E. SIRT5 regulates both cytosolic and mitochondrial protein malonylation with glycolysis as a major target. Mol Cell 59: 321–332, 2015.
249. Nogueiras R, Habegger KM, Chaudhary N, Finan B, Banks AS, Dietrich MO, Horvath TL, Sinclair DA, Pfluger PT, and Tschop MH. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev 92: 1479–1514, 2012.
250. O'Neill AB, Morgan SJ, and Brioni JD. Histological and behavioral protection by (-)-nicotine against quinolinic acid-induced neurodegeneration in the hippocampus. Neurobiol Learn Mem 69: 46–64, 1998.
251. Oblong JE. The evolving role of the NAD+/nicotinamide metabolome in skin homeostasis, cellular bioenergetics, and aging. DNA Repair (Amst) 23: 59–63, 2014.
252. Obrenovitch TP. Quinolinic acid accumulation during neuroinflammation. Does it imply excitotoxicity? Ann N Y Acad Sci 939: 1–10, 2001.
253. Obrenovitch TP and Urenjak J. Accumulation of quinolinic acid with neuroinflammation: does it mean excitotoxicity? Adv Exp Med Biol 527: 147–154, 2003.
254. Ohashi K, Kawai S, and Murata K. Secretion of quinolinic acid, an intermediate in the kynurenine pathway, for utilization in NAD+ biosynthesis in the yeast Saccharomyces cerevisiae. Eukaryot Cell 12: 648–653, 2013.
255. Oliver E. Diets of cereals & other vegetable proteins & cutaneous pellegra in our country [in Spanish]. Rev Esp Enferm Apar Dig Nutr 17: 68–73, 1958.
256. Olvera-Garcia G, Espinosa E, Sieg SF, and Lederman MM. Cytomegalovirus-specific responses of CD38(+) memory T cells are skewed towards IFN-gamma and dissociated from CD154 in HIV-1 infection. AIDS 28: 311–316, 2014.
257. Palcic MM, Antoun M, Tanizawa K, Soda K, and Floss HG. Stereochemistry of the kynureninase reaction. J Biol Chem 260: 5248–5251, 1985.
258. Penberthy WT. Nicotinic acid-mediated activation of both membrane and nuclear receptors towards therapeutic glucocorticoid mimetics for treating multiple sclerosis. PPAR Res 2009: 853707, 2009.
259. Penberthy WT and Tsunoda I. The importance of NAD in multiple sclerosis. Curr Pharm Des 15: 64–99, 2009.
260. Peng Q, Jia SH, Parodo J, Ai Y, and Marshall JC. Pre-B cell colony enhancing factor induces Nampt-dependent translocation of the insulin receptor out of lipid microdomains in A549 lung epithelial cells. Am J Physiol Endocrinol Metab 308: E324–E333, 2015.
261. Peters JC. Tryptophan nutrition and metabolism: an overview. Adv Exp Med Biol 294: 345–358, 1991.
262. Phillips RS. Structure and mechanism of kynureninase. Arch Biochem Biophys 544: 69–74, 2014.
263. Pissios P. Nicotinamide N-methyltransferase: more than a vitamin B3 clearance enzyme. Trends Endocrinol Metab 28: 340–353, 2017.
264. Puri BK, Hirsch SR, Easton T, and Richardson AJ. A volumetric biochemical niacin flush-based index that noninvasively detects fatty acid deficiency in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 26: 49–52, 2002.
265. Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, Zhao W, Thiyagarajan M, MacGrogan D, Rodgers JT, Puigserver P, Sadoshima J, Deng H, Pedrini S, Gandy S, Sauve AA, and Pasinetti GM. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 281: 21745–21754, 2006.
266. Qiu X, Brown K, Hirschey MD, Verdin E, and Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab 12: 662–667, 2010.
267. Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, and Guillemin GJ. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One 4: e6344, 2009.
268. Rajakumar SV, Lu B, Crikis S, Robson SC, d'Apice AJ, Cowan PJ, and Dwyer KM. Deficiency or inhibition of CD73 protects in mild kidney ischemia-reperfusion injury. Transplantation 90: 1260–1264, 2010.
269. Rajamohan SB, Pillai VB, Gupta M, Sundaresan NR, Birukov KG, Samant S, Hottiger MO, and Gupta MP. SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol Cell Biol 29: 4116–4129, 2009.
270. Ramautar A, Mabandla M, Blackburn J, and Daniels WM. Inhibition of HIV-1 tat-induced transactivation and apoptosis by the divalent metal chelators, fusaric acid and picolinic acid-implications for HIV-1 dementia. Neurosci Res 74: 59–63, 2012.
271. Rankin PW, Jacobson EL, Benjamin RC, Moss J, and Jacobson MK. Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo. J Biol Chem 264: 4312–4317, 1989.
272. Ratajczak J, Joffraud M, Trammell SA, Ras R, Canela N, Boutant M, Kulkarni SS, Rodrigues M, Redpath P, Migaud ME, Auwerx J, Yanes O, Brenner C, and Canto C. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat Commun 7: 13103, 2016.
273. Rawling JM, ApSimon MM, and Kirkland JB. Lung poly(ADP-ribose) and NAD+ concentrations during hyperoxia and niacin deficiency in the Fischer-344 rat. Free Radic Biol Med 20: 865–871, 1996.
274. Rawling JM, Jackson TM, Driscoll ER, and Kirkland JB. Dietary niacin deficiency lowers tissue poly(ADP-ribose) and NAD+ concentrations in Fischer-344 rats. J Nutr 124: 1597–1603, 1994.
275. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, and Imai S. Nampt/PBEF/visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6: 363–375, 2007.
276. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, and Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1 alpha and SIRT1. Nature 434: 113–118, 2005.
277. This reference has been deleted.
278. Roessler C, Tuting C, Meleshin M, Steegborn C, and Schutkowski M. A Novel continuous assay for the deacylase sirtuin 5 and other deacetylases. J Med Chem 58: 7217–7223, 2015.
279. Rojas A, Stratford MR, Bentzen SM, and Denekamp J. Is sensitization with nicotinamide and carbogen dependent on nicotinamide concentration at the time of irradiation? Int J Radiat Biol 80: 499–506, 2004.
280. Romashkan SV, Das SK, Villareal DT, Ravussin E, Redman LM, Rochon J, Bhapkar M, and Kraus WE; CALERIE Study Group. Safety of two-year caloric restriction in non-obese healthy individuals. Oncotarget 7: 19124–19133, 2016.
281. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, and Andris F. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 32: 3225–3234, 2002.
282. Rothgiesser KM, Erener S, Waibel S, Luscher B, and Hottiger MO. SIRT2 regulates NF-kappaB dependent gene expression through deacetylation of p65 Lys310. J Cell Sci 123: 4251–4258, 2010.
283. Ruddock MW and Hirst DG. Nicotinamide relaxes vascular smooth muscle by inhibiting myosin light chain kinase-dependent signaling pathways: implications for anticancer efficacy. Oncol Res 14: 483–489, 2004.
284. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, and Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med 11: 1306–1313, 2005.
285. Sakiyama Y. Purine nucleoside phosphorylase deficiency [in Japanese]. Ryoikibetsu Shokogun Shirizu 32: 43–45, 2000.
286. Sanchez WY, Obispo C, Ryan E, Grice JE, and Roberts MS. Changes in the redox state and endogenous fluorescence of in vivo human skin due to intrinsic and photo-aging, measured by multiphoton tomography with fluorescence lifetime imaging. J Biomed Opt 18: 061217, 2013.
287. Sartini D, Santarelli A, Rossi V, Goteri G, Rubini C, Ciavarella D, Lo Muzio L, and Emanuelli M. Nicotinamide N-methyltransferase upregulation inversely correlates with lymph node metastasis in oral squamous cell carcinoma. Mol Med 13: 415–421, 2007.
288. Sasaki Y, Araki T, and Milbrandt J. Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. J Neurosci 26: 8484–8491, 2006.
289. Sasaki Y, Vohra BP, Lund FE, and Milbrandt J. Nicotinamide mononucleotide adenylyl transferase-mediated axonal protection requires enzymatic activity but not increased levels of neuronal nicotinamide adenine dinucleotide. J Neurosci 29: 5525–5535, 2009.
290. Satoh A, Brace CS, Rensing N, Cliften P, Wozniak DF, Herzog ED, Yamada KA, and Imai S. Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab 18: 416–430, 2013.
291. Sauer AV, Brigida I, Carriglio N, and Aiuti A. Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency. Front Immunol 3: 265, 2012.
292. Sauve AA, Moir RD, Schramm VL, and Willis IM. Chemical activation of Sir2-dependent silencing by relief of nicotinamide inhibition. Mol Cell 17: 595–601, 2005.
293. Scheibye-Knudsen M, Mitchell SJ, Fang EF, Iyama T, Ward T, Wang J, Dunn CA, Singh N, Veith S, Hasan-Olive MM, Mangerich A, Wilson MA, Mattson MP, Bergersen LH, Cogger VC, Warren A, Le Couteur DG, Moaddel R, Wilson DM 3rd, Croteau DL, de Cabo R, and Bohr VA. A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in cockayne syndrome. Cell Metab 20: 840–855, 2014.
294. Schlicker C, Gertz M, Papatheodorou P, Kachholz B, Becker CF, and Steegborn C. Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. J Mol Biol 382: 790–801, 2008.
295. Schreiber V, Dantzer F, Ame JC, and de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7: 517–528, 2006.
296. Schweiger M, Hennig K, Lerner F, Niere M, Hirsch-Kauffmann M, Specht T, Weise C, Oei SL, and Ziegler M. Characterization of recombinant human nicotinamide mononucleotide adenylyl transferase (NMNAT), a nuclear enzyme essential for NAD synthesis. FEBS Lett 492: 95–100, 2001.
297. Seman M, Adriouch S, Scheuplein F, Krebs C, Freese D, Glowacki G, Deterre P, Haag F, and Koch-Nolte F. NAD-induced T cell death: ADP-ribosylation of cell surface proteins by ART2 activates the cytolytic P2X7 purinoceptor. Immunity 19: 571–582, 2003.
298. Semba RD. The discovery of the vitamins. Int J Vitam Nutr Res 82: 310–315, 2012.
299. Semba RD. The historical evolution of thought regarding multiple micronutrient nutrition. J Nutr 142: 143S–156S, 2012.
300. Sharma A, Diecke S, Zhang WY, Lan F, He C, Mordwinkin NM, Chua KF, and Wu JC. The role of SIRT6 protein in aging and reprogramming of human induced pluripotent stem cells. J Biol Chem 288: 18439–18447, 2013.
301. Shetty PK, Galeffi F, and Turner DA. Nicotinamide pre-treatment ameliorates NAD(H) hyperoxidation and improves neuronal function after severe hypoxia. Neurobiol Dis 62: 469–478, 2014.
302. Shi H, Sun N, Mayevsky A, Zhang Z, and Luo Q. Preclinical evidence of mitochondrial nicotinamide adenine dinucleotide as an effective alarm parameter under hypoxia. J Biomed Opt 19: 17005, 2014.
303. Shi W, Hegeman MA, van Dartel DA, Tang J, Suarez M, Swarts H, van der Hee B, Arola L, and Keijer J. Effects of a wide range of dietary nicotinamide riboside (NR) concentrations on metabolic flexibility and white adipose tissue (WAT) of mice fed a mildly obesogenic diet. Mol Nutr Food Res 61: 1600878, 2017.
304. Shibata K. True niacin deficiency in quinolinic acid phosphoribosyltransferase (QPRT) knockout mice. J Nutr Sci Vitaminol (Tokyo) 61(Suppl): S145–S147, 2015.
305. Shibata K and Fukuwatari T. Large amounts of picolinic acid are lethal but small amounts increase the conversion of tryptophan-nicotinamide in rats. J Nutr Sci Vitaminol (Tokyo) 60: 334–339, 2014.
306. Shibata K, Mushiage M, Kondo T, Hayakawa T, and Tsuge H. Effects of vitamin B6 deficiency on the conversion ratio of tryptophan to niacin. Biosci Biotechnol Biochem 59: 2060–2063, 1995.
307. Shibata K, Ohno T, Sano M, and Fukuwatari T. The urinary ratio of 3-hydroxykynurenine/3-hydroxyanthranilic acid is an index to predicting the adverse effects of d-tryptophan in rats. J Nutr Sci Vitaminol (Tokyo) 60: 261–268, 2014.
308. Siegel MP, Kruse SE, Knowels G, Salmon A, Beyer R, Xie H, Van Remmen H, Smith SR, and Marcinek DJ. Reduced coupling of oxidative phosphorylation in vivo precedes electron transport chain defects due to mild oxidative stress in mice. PLoS One 6: e26963, 2011.
309. Sinclair DA and Guarente L. Extrachromosomal rDNA circles—a cause of aging in yeast. Cell 91: 1033–1042, 1997.
310. Sociali G, Raffaghello L, Magnone M, Zamporlini F, Emionite L, Sturla L, Bianchi G, Vigliarolo T, Nahimana A, Nencioni A, Raffaelli N, and Bruzzone S. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model. Oncotarget 7: 2968–2984, 2016.
311. Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C, Tanokura M, Denu JM, and Prolla TA. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 143: 802–812, 2010.
312. Song J, Keppler BD, Wise RR, and Bent AF. PARP2 is the predominant poly(ADP-ribose) polymerase in Arabidopsis DNA damage and immune responses. PLoS Genet 11: e1005200, 2015.
313. Sono M. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 2. Evidence for the existence of another binding site in the enzyme for indole derivative effectors. Biochemistry 28: 5400–5407, 1989.
314. Soudijn W, van Wijngaarden I, and Ijzerman AP. Nicotinic acid receptor subtypes and their ligands. Med Res Rev 27: 417–433, 2007.
314a. Southam CM and Ehrlich J. Effects of extracts of western red-cedar heartwood on certain wood-decaying fungi in culture. Phytopathology 33: 517–524, 1943.
315. Spaans SK, Weusthuis RA, van der Oost J, and Kengen SW. NADPH-generating systems in bacteria and archaea. Front Microbiol 6: 742, 2015.
316. Spinnler R, Gorski T, Stolz K, Schuster S, Garten A, Beck-Sickinger AG, Engelse MA, de Koning EJ, Korner A, Kiess W, and Maedler K. The adipocytokine Nampt and its product NMN have no effect on beta-cell survival but potentiate glucose stimulated insulin secretion. PLoS One 8: e54106, 2013.
317. Stratford MR, Dennis MF, Hoskin P, Phillips H, Hodgkiss RJ, and Rojas A. Nicotinamide pharmacokinetics in humans: effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring. Br J Cancer 74: 16–21, 1996.
318. Sun S, Cheng S, Zhu Y, Zhang P, Liu N, Xu T, Sun C, and Lv Y. Identification of PRKDC (protein kinase, DNA-activated, catalytic polypeptide) as an essential gene for colorectal cancer (CRCs) cells. Gene 584: 90–96, 2016.
319. Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A, and Gupta MP. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest 119: 2758–2771, 2009.
320. Surjana D, Halliday GM, and Damian DL. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. J Nucleic Acids 2010: 157591, 2010.
321. Surjana D, Halliday GM, Martin AJ, Moloney FJ, and Damian DL. Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials. J Invest Dermatol 132: 1497–1500, 2012.
322. Suzuki K and Koike T. Mammalian Sir2-related protein (SIRT) 2-mediated modulation of resistance to axonal degeneration in slow Wallerian degeneration mice: a crucial role of tubulin deacetylation. Neuroscience 147: 599–612, 2007.
323. Szkudelski T, Zywert A, and Szkudelska K. Metabolic disturbances and defects in insulin secretion in rats with streptozotocin-nicotinamide-induced diabetes. Physiol Res 62: 663–670, 2013.
324. Takahashi R. Anti-aging studies on the senescence accelerated mouse (SAM) strains [in Japanese]. Yakugaku Zasshi 130: 11–18, 2010.
325. Tang K, Sham H, Hui E, and Kirkland JB. Niacin deficiency causes oxidative stress in rat bone marrow cells but not through decreased NADPH or glutathione status. J Nutr Biochem 19: 746–753, 2008.
326. Tang KS, Suh SW, Alano CC, Shao Z, Hunt WT, Swanson RA, and Anderson CM. Astrocytic poly(ADP-ribose) polymerase-1 activation leads to bioenergetic depletion and inhibition of glutamate uptake capacity. Glia 58: 446–457, 2010.
327. Taniguchi A. PNP (purine nucleoside phosphorylase) deficiency [in Japanese]. Nihon Rinsho 61(Suppl 1): 372–376, 2003.
328. Tanno O, Ota Y, Kitamura N, Katsube T, and Inoue S. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br J Dermatol 143: 524–531, 2000.
329. Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, Jiang H, Kim HS, Flynn CR, Hill S, Hayes McDonald W, Olivier AK, Spitz DR, and Gius D. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol Cell 40: 893–904, 2010.
330. Tao R, Kim SH, Honbo N, Karliner JS, and Alano CC. Minocycline protects cardiac myocytes against simulated ischemia-reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1. J Cardiovasc Pharmacol 56: 659–668, 2010.
331. Tempel W, Rabeh WM, Bogan KL, Belenky P, Wojcik M, Seidle HF, Nedyalkova L, Yang T, Sauve AA, Park HW, and Brenner C. Nicotinamide riboside kinase structures reveal new pathways to NAD+. PLoS Biol 5: e263, 2007.
332. Terada N, Kinoshita K, Taguchi S, and Tokuda Y. Wernicke encephalopathy and pellagra in an alcoholic and malnourished patient. BMJ Case Rep 2015: bcr2015209412, 2015.
333. Ting KK, Brew BJ, and Guillemin GJ. Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J Neuroinflammation 6: 36, 2009.
334. Tong DL, Zhang DX, Xiang F, Teng M, Jiang XP, Hou JM, Zhang Q, and Huang YS. Nicotinamide pretreatment protects cardiomyocytes against hypoxia-induced cell death by improving mitochondrial stress. Pharmacology 90: 11–18, 2012.
335. Trammell SA and Brenner C. Targeted, LCMS-based metabolomics for quantitative measurement of NAD(+) metabolites. Comput Struct Biotechnol J 4: e201301012, 2013.
336. Trammell SA and Brenner C. NNMT: a bad actor in fat makes good in liver. Cell Metab 22: 200–201, 2015.
337. Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, and Brenner C. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun 7: 12948, 2016.
338. Trammell SA, Yu L, Redpath P, Migaud ME, and Brenner C. Nicotinamide riboside is a major NAD+ precursor vitamin in cow milk. J Nutr 146: 957–963, 2016.
339. Tran MT, Zsengeller ZK, Berg AH, Khankin EV, Bhasin MK, Kim W, Clish CB, Stillman IE, Karumanchi SA, Rhee EP, and Parikh SM. PGC1alpha drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature 531: 528–532, 2016.
340. Tummala KS, Gomes AL, Yilmaz M, Grana O, Bakiri L, Ruppen I, Ximenez-Embun P, Sheshappanavar V, Rodriguez-Justo M, Pisano DG, Wagner EF, and Djouder N. Inhibition of de novo NAD(+) synthesis by oncogenic URI causes liver tumorigenesis through DNA damage. Cancer Cell 26: 826–839, 2014.
341. Turunc Bayrakdar E, Uyanikgil Y, Kanit L, Koylu E, and Yalcin A. Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Abeta(1–42)-induced rat model of Alzheimer's disease. Free Radic Res 48: 146–158, 2014.
342. Ugur S, Ulu R, Dogukan A, Gurel A, Yigit IP, Gozel N, Aygen B, and Ilhan N. The renoprotective effect of curcumin in cisplatin-induced nephrotoxicity. Ren Fail 37: 332–336, 2015.
343. Vaccari CS, Nagamia S, Thoenes M, Oguchi A, Hammoud R, and Khan BV. Efficacy of controlled-release niacin in treatment of metabolic syndrome: correlation to surrogate markers of atherosclerosis, vascular reactivity, and inflammation. J Clin Lipidol 1: 605–613, 2007.
344. Vakhrusheva O, Smolka C, Gajawada P, Kostin S, Boettger T, Kubin T, Braun T, and Bober E. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res 102: 703–710, 2008.
345. van der Hoorn JW, de Haan W, Berbee JF, Havekes LM, Jukema JW, Rensen PC, and Princen HM. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 28: 2016–2022, 2008.
346. Vaquero A, Sternglanz R, and Reinberg D. NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs. Oncogene 26: 5505–5520, 2007.
347. Vazquez BN, Thackray JK, and Serrano L. Sirtuins and DNA damage repair: SIRT7 comes to play. Nucleus 8: 107–115, 2017.
348. Verdin E. NAD(+) in aging, metabolism, and neurodegeneration. Science 350: 1208–1213, 2015.
349. Vohra BP, Sasaki Y, Miller BR, Chang J, DiAntonio A, and Milbrandt J. Amyloid precursor protein cleavage-dependent and -independent axonal degeneration programs share a common nicotinamide mononucleotide adenylyltransferase 1-sensitive pathway. J Neurosci 30: 13729–13738, 2010.
350. Wang F, Nguyen M, Qin FX, and Tong Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell 6: 505–514, 2007.
351. Wang F and Zhang WP. Research progress on nicotinamide phosphoribosyl transferase involved in aging and age-related diseases [in Chinese]. Zhejiang Da Xue Xue Bao Yi Xue Ban 40: 680–684, 2011.
352. Wang H, Liang X, Luo G, Ding M, and Liang Q. Protection effect of nicotinamide on cardiomyoblast hypoxia/re-oxygenation injury: study of cellular mitochondrial metabolism. Mol Biosyst 12: 2257–2264, 2016.
353. Wang P, Du H, Zhang RY, Guan YF, Xu TY, Xu QY, Su DF, and Miao CY. Circulating and local visfatin/Nampt/PBEF levels in spontaneously hypertensive rats, stroke-prone spontaneously hypertensive rats and Wistar-Kyoto rats. J Physiol Sci 60: 317–324, 2010.
354. Wang P and Miao CY. NAMPT as a therapeutic target against stroke. Trends Pharmacol Sci 36: 891–905, 2015.
355. Wang P, Xu TY, Guan YF, Su DF, Fan GR, and Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 81: 370–380, 2009.
356. Wang X, Hu X, Yang Y, Takata T, and Sakurai T. Nicotinamide mononucleotide protects against beta-amyloid oligomer-induced cognitive impairment and neuronal death. Brain Res 1643: 1–9, 2016.
357. Warburg O and Christian W. Pyridine, the hydrogen transferring element of fermentation enzymes (Pyridine-nucleotide.). Biochemische Zeitschrift 287: 291–328, 1936.
358. Wardman P. Hypoxic cell radiosensitizers—chemical aspects and in vitro models. Strahlentherapie Sonderb 75: 20–26, 1978.
359. Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol) 19: 397–417, 2007.
360. Wei CC, Kong YY, Li GQ, Guan YF, Wang P, and Miao CY. Nicotinamide mononucleotide attenuates brain injury after intracerebral hemorrhage by activating Nrf2/HO-1 signaling pathway. Sci Rep 7: 717, 2017.
361. Wei M, Fabrizio P, Hu J, Ge H, Cheng C, Li L, and Longo VD. Life span extension by calorie restriction depends on Rim15 and transcription factors downstream of Ras/PKA, Tor, and Sch9. PLoS Genet 4: e13, 2008.
362. Weidele K, Beneke S, and Burkle A. The NAD+ precursor nicotinic acid improves genomic integrity in human peripheral blood mononuclear cells after X-irradiation. DNA Repair (Amst) 52: 12–23, 2017.
363. Whitacre CM, Hashimoto H, Tsai ML, Chatterjee S, Berger SJ, and Berger NA. Involvement of NAD-poly(ADP-ribose) metabolism in p53 regulation and its consequences. Cancer Res 55: 3697–3701, 1995.
364. Wiley CA. Quinolinic acid and neurodegeneration in AIDS. J Neurovirol 1: 328–329, 1995.
365. Williams AC, Hill LJ, and Ramsden DB. Nicotinamide, NAD(P)(H), and methyl-group homeostasis evolved and became a determinant of ageing diseases: hypotheses and lessons from pellagra. Curr Gerontol Geriatr Res 2012: 302875, 2012.
366. Williams AC and Ramsden DB. Autotoxicity, methylation and a road to the prevention of Parkinson's disease. J Clin Neurosci 12: 6–11, 2005.
367. Wojcik M, Seidle HF, Bieganowski P, and Brenner C. Glutamine-dependent NAD+ synthetase. How a two-domain, three-substrate enzyme avoids waste. J Biol Chem 281: 33395–33402, 2006.
368. Wood JD and Peesker SJ. The effect on GABA metabolism in brain of isonicotinic acid hydrazide and pyridoxine as a fuction of time after administration. J Neurochem 19: 1527–1537, 1972.
369. Wu W, Nicolazzo JA, Wen L, Chung R, Stankovic R, Bao SS, Lim CK, Brew BJ, Cullen KM, and Guillemin GJ. Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain. PLoS One 8: e59749, 2013.
370. Yang H, Zuo XZ, Tian C, He DL, Yi WJ, Chen Z, Zhang PW, Ding SB, and Ying CJ. Green tea polyphenols attenuate high-fat diet-induced renal oxidative stress through SIRT3-dependent deacetylation. Biomed Environ Sci 28: 455–459, 2015.
371. Yang SJ, Choi JM, Kim L, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, and Park CY. Nicotinamide improves glucose metabolism and affects the hepatic NAD-sirtuin pathway in a rodent model of obesity and type 2 diabetes. J Nutr Biochem 25: 66–72, 2014.
372. Yao Z, Yang W, Gao Z, and Jia P. Nicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer disease. Neurosci Lett 647: 133–140, 2017.
373. Yin F, Boveris A, and Cadenas E. Mitochondrial energy metabolism and redox signaling in brain aging and neurodegeneration. Antioxid Redox Signal 20: 353–371, 2014.
374. Yoon J, Lee KJ, Oh GS, Kim GH, and Kim SW. Regulation of Nampt expression by transcriptional coactivator NCOA6 in pancreatic beta-cells. Biochem Biophys Res Commun 487: 600–606, 2017.
375. Yoshino J, Baur JA, and Imai SI. NAD(+) intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab 27: 513–528, 2018.
376. Yoshino J, Mills KF, Yoon MJ, and Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab 14: 528–536, 2011.
377. Young GS, Choleris E, Lund FE, and Kirkland JB. Decreased cADPR and increased NAD+ in the Cd38−/− mouse. Biochem Biophys Res Commun 346: 188–192, 2006.
378. Young GS, Jacobson EL, and Kirkland JB. Water maze performance in young male Long-Evans rats is inversely affected by dietary intakes of niacin and may be linked to levels of the NAD+ metabolite cADPR. J Nutr 137: 1050–1057, 2007.
379. Yu J, Sadhukhan S, Noriega LG, Moullan N, He B, Weiss RS, Lin H, Schoonjans K, and Auwerx J. Metabolic characterization of a Sirt5 deficient mouse model. Sci Rep 3: 2806, 2013.
380. Zeng J, Libien J, Shaik F, Wolk J, and Hernandez AI. Nucleolar PARP-1 expression is decreased in Alzheimer's disease: consequences for epigenetic regulation of rDNA and cognition. Neural Plast 2016: 8987928, 2016.
381. Zhai RG, Cao Y, Hiesinger PR, Zhou Y, Mehta SQ, Schulze KL, Verstreken P, and Bellen HJ. Drosophila NMNAT maintains neural integrity independent of its NAD synthesis activity. PLoS Biol 4: e416, 2006.
382. Zhai RG, Zhang F, Hiesinger PR, Cao Y, Haueter CM, and Bellen HJ. NAD synthase NMNAT acts as a chaperone to protect against neurodegeneration. Nature 452: 887–891, 2008.
383. Zhang B, Muller-Steffner H, Schuber F, and Potter BVL. Nicotinamide 2-fluoroadenine dinucleotide unmasks the NAD(+) glycohydrolase activity of Aplysia californica adenosine 5′-diphosphate ribosyl cyclase. Biochemistry 46: 4100–4109, 2007.
384. Zhong L, D'Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, Guimaraes A, Marinelli B, Wikstrom JD, Nir T, Clish CB, Vaitheesvaran B, Iliopoulos O, Kurland I, Dor Y, Weissleder R, Shirihai OS, Ellisen LW, Espinosa JM, and Mostoslavsky R. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 140: 280–293, 2010.
385. Zhong L, Yeh TY, Hao J, Pourtabatabaei N, Mahata SK, Shao J, Chessler SD, and Chi NW. Nutritional energy stimulates NAD+ production to promote tankyrase-mediated PARsylation in insulinoma cells. PLoS One 10: e0122948, 2015.
386. Zhou SS, Li D, Sun WP, Guo M, Lun YZ, Zhou YM, Xiao FC, Jing LX, Sun SX, Zhang LB, Luo N, Bian FN, Zou W, Dong LB, Zhao ZG, Li SF, Gong XJ, Yu ZG, Sun CB, Zheng CL, Jiang DJ, and Li ZN. Nicotinamide overload may play a role in the development of type 2 diabetes. World J Gastroenterol 15: 5674–5684, 2009.
387. Zhou SS, Li D, and Zhou Y. Letter to the editor: high serum N(1)-methylnicotinamide in obesity and diabetes: a consequence of excess nicotinamide? J Clin Endocrinol Metab 100: L78–L79, 2015.
388. Zhou Y, Wang L, Yang F, Lin X, Zhang S, and Zhao ZK. Determining the extremes of the cellular NAD(H) level by using an Escherichia coli NAD(+)-auxotrophic mutant. Appl Environ Microbiol 77: 6133–6140, 2011.
389. Zhu XH, Lu M, Lee BY, Ugurbil K, and Chen W. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc Natl Acad Sci U S A 112: 2876–2881, 2015.
390. Zhuo L, Fu B, Bai X, Zhang B, Wu L, Cui J, Cui S, Wei R, Chen X, and Cai G. NAD blocks high glucose induced mesangial hypertrophy via activation of the sirtuins-AMPK-mTOR pathway. Cell Physiol Biochem 27: 681–690, 2011.
391. Zykova TA, Zhu F, Zhai X, Ma WY, Ermakova SP, Lee KW, Bode AM, and Dong Z. Resveratrol directly targets COX-2 to inhibit carcinogenesis. Mol Carcinog 47: 797–805, 2008.
Information & Authors
Information
Published In
Antioxidants & Redox Signaling
Volume 30 • Issue Number 2 • January 10, 2019
Pages: 251 - 294
PubMed: 29634344
Copyright
Copyright 2019, Mary Ann Liebert, Inc., publishers.
History
Published in print: January 10, 2019
Published online: 30 November 2018
Published ahead of print: 11 May 2018
Published ahead of production: 12 March 2018
Accepted: 22 February 2018
Revision received: 22 February 2018
Received: 6 July 2017
Topics
Authors
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.